

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



1st August, 2022

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400051.

Dear Sir,

Subject: Intimation to Stock Exchanges under Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI LODR Regulations"], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 1st August, 2022:

- The un-audited financial results for the quarter ended 30th June, 2022 along with the Auditor's Limited Review Report thereon (Enclosed herewith) have been adopted by the Board.
- The Board has taken note of the Resignation email of Ms. Taruni Banda, Company Secretary and Compliance officer dated June 27th, 2022, has accepted/approved the Resignation and relieved her from all responsibilities w.e.f 6th August, 2022.
- The Board report and annexures have been approved for the 30th Annual General meeting.

Kindly note that the meeting was commenced at 2.30 PM and concluded at 4.00 PM

You are requested to take note of the above.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFO /CMD/4/2015 dated September 09, 2015 are enclosed herewith Annexure II.

Thanking You,
Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Taruni Banda
Company Secretary

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



Details under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read along SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 with respect to resignation of Company Secretary & Compliance Officer and KMP of the Company

Ms. Taruni Banda, Company Secretary and Compliance officer has submitted her resignation via email dated June 27th, 2022 stating to relieve her within one month. She has disclosed that she cannot continue with the position due to her personal reasons.




For Krebs Biochemicals & Industries Limited


Taruni Banda

Company Secretary



Annexure-VI

 Reply  Reply All  Forward

Mon 6/27/2022 1:39 PM

 Taruni <com_sec@krebsbiochem.com>

Resignation-Taruni (Company secretary)

To 'Pabitra Bhattacharya - Operations, Mumbai'; 'Pabitra Bhattacharya'; 'Prasad Gvi (guvela@gmail.com)'; 'R T Ravi' (vfpl.rtravi@gmail.com); ...
Cc 'tarunibanda05@gmail.com'; 'Harish Kamath - Company Secretary, Mumbai'

Dear Board of Directors,
Krebs biochemical and Industries limited

It is with utmost dismay and with a heavy heart I put forward to you that I am resigning from the position of company secretary and compliance officer of Krebs Biochemicals and Industries limited due to my health reasons and a baby in hand.

I request the Board to consider my resignation and relieve me with in one month from today, clear my Full and final settlement and also file the necessary forms with ROC and stock exchange to remove my name from the KMP list.

I thank all the board of directors who have helped me in this 3 years of my journey in Krebs which has enhanced my knowledge and overall personality.


Thanks and Regards

Taruni Banda

Company Secretary

Krebs Biochemicals and Industries Limited

"Success comes with consistency"

 See more about Taruni.



KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031


Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

Additional disclosures as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sl No	Particulars	As at 30-06-2022		As at 31-03-2022	
1	Debt-equity ratio [no.of times]*	(1.81)		(1.91)	
2	i) Last due date for the payment of dividend of Non-convertible Redeemable preference shares (NCRPS)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA		NA	
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA		NA	
	ii) Whether Dividend has been paid on due dates	NA		NA	
3	i) Last due date for the repayment of principal of NCRPS	NA		NA	
	ii) Whether principal has been repaid on due dates	NA		NA	
4	Next due date and amount for payment of dividend of NCRPS	(Rs.Lacs)	Date	(Rs.Lacs)	Date
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA	NA	NA	NA
5	Next due date and amount for the repayment of principal of NCRPS (falling due within next one year period)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA	NA	NA	NA
6	Next due date and amount for the repayment of principal of CPs (falling due within next one year period)	NA	NA	NA	NA
	Particulars	As at 30-06-2022		As at 31-03-2022	
		(Rs.Lacs)		(Rs.Lacs)	
7	Debt Service Coverage ratio **	(0.04)		(0.22)	
8	Interest Service coverage ratio ***	(25.74)		(7.26)	
9	Outstanding redeemable preference shares (quantity and value)				
	Quantity	130.00		130.00	
	Value	13,000.00		13,000.00	
10	Capital redemption reserve/debenture redemption reserve	-		-	
11	Net Worth****	(9,467.46)		(8,653.79)	
12	Net Profit/(Loss) after tax (Including Other comprehensive Income)	(813.67)		(4,487.32)	
13	Earning per share	(3.77)		(20.81)	

Note:

- * Debt-Equity Ratio = Total Borrowings divided by Equity
- ** DSCR = EBITDA (Earnings before interest, Tax, depreciation and Amortization) divided by (Interest expenses & principal amount on Short & Long Tem borrowings)
- *** ISCR = Profit before interest and exceptional items divided by interest expense
- **** Net worth as per section 2(57) of Companies Act, 2013 (aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation).
- The above results have been reviewed by the Audit Committee at its meeting held on 01st August, 2022 and approved by the Board of Directors of the Company at its meeting held on 01st August, 2022.


Pabitra Kumar Kalipada Bhattacharyya
 Managing Director
 DIN :07131152

Place: Hyderabad
Date:01.08.2022

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034


STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
	PART - 1				
1	Revenue from Operations				
	a) Net Sales / Income from Operations	992.37	1,780.49	539.50	5,294.06
	b) Other Operating Income	71.69	135.26	136.04	676.25
2	Other Income	12.93	79.28	2.98	115.58
3	Total Income from operations (1+2)	1,076.99	1,995.03	678.52	6,085.89
4	Expenses				
	a) Cost of Material Consumed	1,045.13	1,599.10	442.08	4,618.01
	b) Changes in Inventories of Finished goods, Work-In-Progress	(293.75)	(179.41)	(68.45)	(553.79)
	c) Employee Benefits Expenses	366.18	443.47	330.75	1,530.02
	d) Finance Costs	30.43	27.97	151.16	539.10
	e) Depreciation and Amortisation Expense	169.28	204.87	141.60	629.67
	f) Other Manufacturing Expenses	495.53	893.99	543.43	3,305.78
	g) Other Expenses	77.86	136.43	80.30	469.78
	Total Expenses (4)	1,890.66	3,126.42	1,620.87	10,538.57
5	Profit / (Loss) before exceptional items and tax (3±4)	(813.67)	(1,131.39)	(942.35)	(4,452.68)
6	Exceptional Items:		-	-	-
7	Profit / (Loss) before Tax (5 ± 6)	(813.67)	(1,131.39)	(942.35)	(4,452.68)
8	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	-	-	-
9	Profit / (Loss) for the period (7 ± 8)	(813.67)	(1,131.39)	(942.35)	(4,452.68)
10	Other Comprehensive Income (OCI)				
i	Items that will not be reclassified to profit or Loss	-	-	-	-
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	(30.47)	-	(34.65)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	(30.47)	-	(34.65)
11	Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(813.67)	(1,161.86)	(942.35)	(4,487.33)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity excluding Revaluation Reserve	-	-	-	(10,770.47)
14	Earning Per Share (of Rs.10/- each) (not Annualised)				
	a) Basic	(3.77)	(5.39)	(4.37)	(20.81)
	b) Diluted	(3.77)	(5.39)	(4.37)	(20.81)
15	Net Worth (Including Retained Earnings)	-	-	-	(7,509.32)

See accompanying notes to the Financial results

1	The above results have been reviewed by the Audit Committee at its meeting held on 1st August, 2022 and approved by the Board of Directors of the Company at its meeting held on 1st August, 2022.
2	The Company is operating in one segment only hence no segment results have been disclosed.
3	The figures for the preceding quarter ended 31.03.2022 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year.
4	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.


 Pabitrakumar Kallipada Bhattacharyya
 Managing Director
 DIN :07131152

Place: Hyderabad

Date: 01.08.2022



Independent Auditor's Review Report on the Quarterly Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI(Listing Obligation and Disclosure Requirements)Regulation,2015,as amended

**Review Report to
The Board of Directors,
M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED** ("the company") for the quarter ended **30th June, 2022** (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended(the "Listing Regulations")
- b) The statement, which is the responsibility of the Company's Management and approved by the Board of Directors ,has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani &Co.

Chartered Accountants

Firm Registration No: 012139S

KAVITHA PADMINI
SIRIGINA

Digitally signed by
KAVITHA PADMINI
SIRIGINA

CA S Kavitha Padmini

Partner

Membership no: 229966

UDIN: 22229966ANYYP7160

Place : Hyderabad

Date : 01-08-2022